Loading
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Previous close
$0.7822
−$0.031 · -3.81%
After-hours
$0.815
+$0.0328 · +4.19%
Sep 10, 5:52 PM ET
Regular session · ET · Market data may be delayed.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Day range
Current $0.7822
52-week range
Current $0.7822
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
49
Fair Value
Sentiment
56
Mixed
Risk
84
Extreme Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Day range
Current $0.7822
52-week range
Current $0.7822
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 815.37K USD | 2.52M USD | 58.47K USD | — | — |
| Cost of goods sold | 182.46K USD | 1.47M USD | 1.19M USD | 6.75K USD | 4.89K USD |
| Gross profit | 632.91K USD | 1.06M USD | −1.13M USD | −6.75K USD | −4.89K USD |
| Research and development | −66.13K USD | 154.36K USD | 1.95M USD | 4.13M USD | 1.33M USD |
| Selling, general, and administrative | 7.04M USD | 11.23M USD | 14.77M USD | 9.35M USD | 2.09M USD |
| Operating expenses | 6.98M USD | 57.54M USD | 34.91M USD | 13.48M USD | 3.42M USD |
| Interest income | — | 18 USD | — | — | — |
| Interest expense | 751.01K USD | 1.41M USD | 671.63K USD | — | — |
| Depreciation and amortization | 15.17K USD | 731.35K USD | 43.94K USD | 6.75K USD | 4.89K USD |
| Operating income | −6.34M USD | −56.49M USD | −36.03M USD | −13.48M USD | −3.42M USD |
| Net income | −14.03M USD | −58.69M USD | −37.41M USD | −13.42M USD | −3.42M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 21, 2026 | 1:10 | — | — |
Stock split | Mar 25, 2026 | 1:5 | — | — |
Stock split | Jun 13, 2025 | 1:85 | — | — |
Stock split | Sep 24, 2024 | 1:40 | — | — |
Effective May 21, 2026
1:10
Effective Mar 25, 2026
1:5
Effective Jun 13, 2025
1:85
Effective Sep 24, 2024
1:40
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
